|
|
Article: Spectrum deal strengthens Par pipeline.(Par Pharmaceutical Cos. signs contract with Spectrum Pharmaceuticals Inc.)(Brief article)
- Article from:
- Chain Drug Review
- Article date:
- March 27, 2006
CopyrightCOPYRIGHT 2006 Racher Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SPRING VALLEY, N.Y. -- Par Pharmaceutical Cos. has entered into a product collaboration with Spectrum Pharmaceuticals Inc. in which the former gains access to several generic injectable and ophthalmic products now awaiting Food and Drug Administration approval.
A first-to-file sumatriptan injection (6 mg/0.5 mL) is included in the agreement. The product is the generic version of GlaxoSmithKline PLC's (GSK's) Imitrex, used for the acute treatment of migraine attacks.
"Our collaboration with Spectrum will expand the therapeutic scope as well as the size of Par's generic product pipeline," points out president and chief executive officer Scott Tarriff.
...